Skip to content

NEWGLAB Pharma

Metabolic Anti-Cancer Therapeutics

Menu

Home
Core Technology
Products
R & D
PR Center
- News
- Media
- Book
- Notice
Contact Us

Kofactor 2

You are here: NEWGLAB Pharma > Kofactor 2

Developing in process

United States

NEWGLAB PHARMA, INC.
Address: 701E. Pratt Street, Baltimore, MD 21202
Office: (+1) 443-887-4080
Lab: (+1) 443-887-4081
Fax: (+1) 410-234-8896
Email: contact@newglabpharma.com
Website: www.newglabpharma.com

Korea

NEWGLAB PHARMA KOREA Co., Ltd.
Address: 13F, 479, Bongeunsa-ro, Gungnam-gu, Seoul, Korea (06095)
Email: contact@newglabpharma.com
Website: www.newglabpharma.com

Recent News

FDA Approval Granted to Begin Clinical Trial
26 January 2022
Three New KOfactor 1 Advanced Products Are Now Available
26 January 2022
Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA
6 May 2020
Acquired ODD status and License-In for additional Indications
27 April 2020
Dietary supplement sales contract with KoDiscovery and Sales started in March
27 April 2020

Suggested Links

Original website
Kofactor store

Visitors Counter

485031

Copyright © 2024 NEWGLAB Pharma. All rights reserved. Website made by Piotr Ułaszewski.

Contact Us